Array BioPharma Slides on Secondary Offering
Array BioPharma saw its shares turn negative early on Thursday after the firm announced a secondary offering.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 158
Halozyme Therapeutics Wins Big on Roche License Agreement
Halozyme Therapeutics saw its shares make a handy gain early on Thursday after the firm announced that it licensed its Enhanze drug-delivery technology to Roche for exclusive development of an “undisclosed therapeutic target.”
Short Sellers Hike Bets in Major Biotechs
The August 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Major Pharma Short Interest Surges
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Mortalities From Car Crashes Represent 2.4% of World’s Deaths
The deadliest parts of the world for road crashes tended to be in South America, Africa, the Middle East and Southeast Asia, while the safest area is Europe.
Merrill Lynch Top Health Care Stock Picks for September: Focus on Large Cap Biotech
According to Merrill Lynch, the health care sector should act as a good hedge against volatility. Even biotech was shown to offer growth at a reasonable price.
BioCryst Pharmaceuticals Announces Secondary Offering
BioCryst Pharmaceuticals watched its shares fall handily on Tuesday after the firm announced a secondary offering.
Sage Therapeutics Gets a Dunce Hat
Sage Therapeutics saw its shares drop by about a quarter early on Tuesday after the firm gave an update on its late-stage study trial in the treatment super-refractory status epilepticus.
Can a New CEO Turn Around Teva?
Often companies that lose their way or face adversity may need a change at the top. Teva Pharmaceutical seems to be the perfect example, and with its change investors are sending the shares much…
Marinus Pharma Wins Big With Mid-Stage Epilepsy Study
Marinus Pharmaceuticals saw its shares make a huge gain to kick off the week after the firm announced top-line results from its mid-stage study in patients with CDKL5 disorder.
Achillion Pharma Slides After Hep C Deal Is Terminated
Achillion Pharmaceuticals saw its shares slump early on Monday after the firm announced that its hepatitis C license and collaboration agreement with Janssen had been terminated.
Kura Oncology Doubles on Mid-Stage Trial Results
Kura Oncology saw its shares double early Friday after the firm announced results from its mid-stage trial in patients with squamous cell carcinomas.
How Bristol-Myers Actually Won by Stopping a Clinical Study
Usually when a clinical study is stopped it spells disaster for the company performing the study, but in this case Bristol-Myers Squibb is bucking that trend and investors are thrilled.
Celgene Faces Multiple Clinical Holds From FDA
Celgene received an update from the FDA early on Thursday. Although shares did not dip initially, this action could prove to be problematic for the biotech giant going forward.
Eli Lilly Hopes to Benefit From Joining the Layoff Brigade — 3,500 Pink Slips!
Eli Lilly is cutting about 8% of its global workforce in a "streamlining and focusing" effort as part of a cost structure initiative.